AbbVie

News

AbbVie hit as CVS says it will cut Humira from formularies

CVS Health has said it will remove AbbVie’s big-selling immunology drug Humira from most of its national formulary lists of reimbursable products, and offer biosimilar ver

News

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, w

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

News

AbbVie cues up filing for c-Met ADC in lung cancer

AbbVie is preparing to file for accelerated approval of telisotuzumab vedotin (Teliso-V) as a treatment for some patients with lung cancer after the drug hit the mark in a

News

MorphoSys shrugs off mixed results for myelofibrosis drug

MorphoSys has said it will press ahead with regulatory filings for its myelofibrosis drug candidate pelabresib, despite mixed results in a phase 3 trial.

News

NICE backs pump-based Parkinson’s drug from AbbVie

A therapy for Parkinson’s disease that can be delivered by a 24-hour subcutaneous infusion pump has been recommended for use by the NHS and could be an option for hundreds

AbbVie hit as CVS says it will cut Humira from formularies

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie cues up filing for c-Met ADC in lung cancer

MorphoSys shrugs off mixed results for myelofibrosis drug

NICE backs pump-based Parkinson’s drug from AbbVie

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

AbbVie

Editor's Picks